BBL
RARE icon

Beck Bode LLC’s Ultragenyx Pharmaceutical RARE Stock Holding History

Beck Bode LLC’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-14,990
Closed -$1.35M – 99
2021
Q3 		$1.35M Buy
+14,990
New +$1.35M 0.38% 48

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Beck Bode LLC's RARE Position: Q4 2021 in Review

Beck Bode LLC sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2021, closing a stake of 14,990 shares — an estimated $1.35M sold.

Beck Bode LLC first reported a position in RARE in Q3 2021 and held it in 1 quarter. The position peaked at $1.35M in Q3 2021. 235 funds tracked by Wall St. Rank hold RARE as of Q4 2021.

  • Beck Bode LLC reported no remaining Ultragenyx Pharmaceutical position as of Q4 2021 after selling out during the quarter.
  • Beck Bode LLC sold 14,990 Ultragenyx Pharmaceutical shares in Q4 2021, an estimated $1.35M.
  • Beck Bode LLC first reported a position in Ultragenyx Pharmaceutical in Q3 2021 and held it in 1 quarter.
  • Beck Bode LLC's Ultragenyx Pharmaceutical position peaked at $1.35M in Q3 2021.
  • 235 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2021.

Based on Beck Bode LLC's 13F filing for Q4 2021, filed 7 Feb 2022.